Unraveling Resistance Mechanisms to Gαq Pathway Inhibition in Uveal Melanoma: Insights from Signaling-Activation Library Screening
These findings support the adaptability of UVM lesions and suggest rational combination therapies targeting both primary <i>GNAQ</i>/<i>GNA11</i>-driven oncogenic signals and their compensatory networks as a more effective, personalized treatment approach for advanced UVM.
Authors
- Monica Acosta (ORCID: https://orcid.org/0000-0003-4202-7765)
- Nadia Arang (ORCID: https://orcid.org/0000-0002-8167-2188)
- Justine S. Paradis
- Simone Lubrano (ORCID: https://orcid.org/0000-0003-4779-5632)
- Gabriela Cuesta-Margolles (ORCID: https://orcid.org/0009-0009-5982-1464)
- Elena Sofia Cardenas-Alcoser
- Kuniaki Sato
- Rodolfo Daniel Cervantes-Villagrana
- J. Silvio Gutkind
Institutions
- University of California, San Francisco (US)
- University of California San Diego (US)
- Quantitative BioSciences (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-12-25
- DOI
- https://doi.org/10.3390/cancers18010074
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Melanoma Research Alliance
- European Commission
- Associazione Italiana per la Ricerca sul Cancro
- National Institutes of Health
- National Cancer Institute